Bone marrow lesions (BMLs) or using older terminology 'Bone marrow edema'is
characterised by excessive water signals in the marrow space on magnetic resonance …

Bone is the most common metastatic site for breast cancer, and bone metastases can cause
pain as well as risk of pathological fractures. Emerging treatments for metastatic bone …

Ipilimumab, an antibody that blocks CTL antigen 4 (CTLA-4), improves overall survival (OS)
for patients with metastatic melanoma. Given its role in angiogenesis and immune evasion …

Purpose: Osteonecrosis of the jaw (ONJ) is a growing concern in patients who receive
bisphosphonates that target osteoclasts. As osteoclasts play multifunctional roles in the …

Background Zoledronic acid treatment reduces the incidence of skeletal-related events
(SREs) in patients with bone metastases from breast, lung, and urologic cancers including …

Bone is the most common site for metastasis in patients with solid tumours.
Bisphosphonates are an effective treatment for preventing skeletal related events and …

The mevalonate pathway (MVP) and the anti‐angiogenic effect of bisphosphonates have
been shown to play a role in the pathogenesis of bisphosphonate‐related osteonecrosis of …

Abstract Development of new materials for the local administration of bisphosphonates
(BPs) is aimed to avoid the negative side effects of prolonged systemic use of these potent …

Osteoclasts are key players in the maintenance of bone, which is an endocrine target and
organ. Bisphosphonates, used for the management of metastatic bone diseases and …

Bone health is an emerging concern in the early breast cancer setting. Current adjuvant
therapies, especially hormonal therapies in premenopausal patients (eg goserelin) and …